Short Interest in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Decreases By 18.1%

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) was the target of a large decrease in short interest in October. As of October 31st, there was short interest totalling 528,200 shares, a decrease of 18.1% from the October 15th total of 644,700 shares. Based on an average trading volume of 159,300 shares, the days-to-cover ratio is presently 3.3 days. Currently, 2.1% of the company’s stock are short sold.

Hedge Funds Weigh In On Vistagen Therapeutics

A number of institutional investors have recently modified their holdings of the company. Jane Street Group LLC purchased a new stake in shares of Vistagen Therapeutics during the 3rd quarter worth about $59,000. HighTower Advisors LLC acquired a new position in Vistagen Therapeutics in the 3rd quarter worth $64,000. Valence8 US LP purchased a new position in Vistagen Therapeutics in the third quarter valued at about $103,000. Blair William & Co. IL boosted its stake in shares of Vistagen Therapeutics by 29.2% during the 2nd quarter. Blair William & Co. IL now owns 88,466 shares of the company’s stock valued at $308,000 after buying an additional 20,000 shares during the last quarter. Finally, American Century Companies Inc. grew its holdings in Vistagen Therapeutics by 49.1% during the 2nd quarter. American Century Companies Inc. now owns 30,315 shares of the company’s stock worth $105,000 after acquiring an additional 9,984 shares in the last quarter. Institutional investors and hedge funds own 78.39% of the company’s stock.

Wall Street Analyst Weigh In

Separately, William Blair raised Vistagen Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th.

Vistagen Therapeutics Price Performance

NASDAQ VTGN opened at $2.63 on Friday. The company has a market capitalization of $73.22 million, a P/E ratio of -2.12 and a beta of 0.78. Vistagen Therapeutics has a 1-year low of $2.58 and a 1-year high of $5.86. The business has a 50 day moving average price of $3.04 and a 200 day moving average price of $3.49.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.